With obesity, immuno-inflammation and oncology driving an increase in CAGR to 2030 of 7.7%, the panel will discuss what this means for the 10 top-selling therapies and the domination of the so-called ‘big drugs for big diseases’.
Highlights:
- Novo and Lilly soar up the company charts, having just entered the top 10 last year.
- Resurgent CNS and respiratory are both prominent among most valuable pipeline candidates
- The prescription drug market will hit $1.7 trillion.
Your Hosts:
Melanie Senior,
Author, World Preview Report
Author, World Preview Report
Daniel Chancellor,
VP, Norstella Thought Leadership
VP, Norstella Thought Leadership
Paul Verdin,
SVP, Consulting & Analytics, Evaluate
SVP, Consulting & Analytics, Evaluate
